Modulating the NOD2/TNF-α signaling axis to balance the induction of mo-DCs and repression of mo-Macs appears to be a promising new target for immunotherapy of colorectal cancer and to treat stricturing complications of CD patients. Here, NOD2 is linked to colorectal cancer.